These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1236 related articles for article (PubMed ID: 22989472)

  • 21. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
    Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
    Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
    Davies M; Speight J
    Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.
    Hartman I; Rojas E; Rodríguez-Molina D
    Am J Ther; 2013; 20(4):384-93. PubMed ID: 23459193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide: effects beyond glycaemic control in diabetes treatment.
    McGill JB
    Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incretins: a new treatment option for type 2 diabetes?
    Geelhoed-Duijvestijn PH
    Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
    Lund A; Knop FK; Vilsbøll T
    Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.
    Barakat GM; Nuwayri-Salti N; Kadi LN; Bitar KM; Al-Jaroudi WA; Bikhazi AB
    Gen Physiol Biophys; 2011 Mar; 30(1):34-44. PubMed ID: 21460410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats.
    Simonsen L; Pilgaard S; Orskov C; Rosenkilde MM; Hartmann B; Holst JJ; Deacon CF
    Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G288-95. PubMed ID: 17431213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
    Lebovitz HE; Banerji MA
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S43-50. PubMed ID: 22650224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.
    Femia AP; Raimondi L; Maglieri G; Lodovici M; Mannucci E; Caderni G
    Int J Cancer; 2013 Nov; 133(10):2498-503. PubMed ID: 23649733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine.
    Anini Y; Izzo A; Oudit GY; Backx PH; Brubaker PL
    Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1599-606. PubMed ID: 17284578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.